Search

Your search keyword '"Schreiber, Stefan"' showing total 783 results

Search Constraints

Start Over You searched for: Author "Schreiber, Stefan" Remove constraint Author: "Schreiber, Stefan" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
783 results on '"Schreiber, Stefan"'

Search Results

1. Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome

5. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort

7. Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease

10. Depression and fatigue six months post-COVID-19 disease are associated with overlapping symptom constellations: A prospective, multi-center, population-based cohort study

11. Effects of lifestyle and associated diseases on serum CC16 suggest complex interactions among metabolism, heart and lungs

12. Tryptophan degradation as a systems phenomenon in inflammation – an analysis across 13 chronic inflammatory diseases

14. Serine metabolism is crucial for cGAS-STING signaling and viral defense control in the gut

15. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study

16. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure

18. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis

20. Cohort profile: the Food Chain Plus (FoCus) cohort

21. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

24. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility

25. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics

27. THU-254-YI Differential gene expression profiles of liver tissue, subcutaneous and visceral adipose tissue delineates severity of MASLD in heavily obese patients

28. Dynamic changes in extracellular vesicle-associated miRNAs elicited by ultrasound in inflammatory bowel disease patients

30. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials

33. Single-cell RNA sequencing of nasal mucosa for molecular and genetic analysis of chemosensory dysfunction in post-COVID patients

34. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme

36. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study

38. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus

39. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study

40. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

41. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

42. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease

43. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity

44. DNA methyltransferase 3A controls intestinal epithelial barrier function and regeneration in the colon

45. Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients

46. Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease

47. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

48. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

49. Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study.

50. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.

Catalog

Books, media, physical & digital resources